Bifidobacterium lactis Lafti® B94


The probiotic strain Bifidobacterium lactis Lafti® B94 has been specifically documented in the area of gut health. It benefits from a strong body of clinical evidence, supported by in vitro and in vivo documentation of its modes of action.

A converging body of clinical evidence: digestive comfort

Gut transit in all population groups (infants from birth, children, adolescents, adults):

  • Bifidobacterium animalis ssp lactis has shown to significantly decrease occasional constipation in adults and children/adolescents as well as other GI health benefits [Larsen et al. 2006; Favretto et al. 2013;Pitkälä 2007]. These studies showed that there were increases in stool frequency and decreases in stool consistency, improvement in normal defecation parameters and frequency compared to placebo. B. lactis LAFTI® B94 significantly improves bloating, belching–abdominal fullness and occasional constipation in children and teens [Basturk, 2016] and helps in occasional diarrhea in infants and children [Erdogan, 2012; Islek, 2014]

Based on two clinical studies in premature infants at risk for Necrotizing Enterocolitis (NEC) [Dilli, 2013; Dilli, 2015] B. lactis Lafti® B94 is safe for babies as it has a GRAS status in the US for use in infant milk formulas. It has also been granted health claims in Canada from birth.

Supportive mechanisms of action

B. lactis Lafti® B94 has been selected and fully documented for its probiotic features in in vitro and in vivo testing:

  • Survival through the digestive tract [Crittenden, 2001 ; Su, 2005].
  • Competition with other microorganisms: H. pylori, S. typhimurium, L. monocytogenes [Zhang, 2008; Crittenden, 2005; Mahoney, 2003].
  • Support of natural defenses [Peran, 2007 ; Pang, 2005].
  • Synergy with prebiotics: B. lactis Lafti® B94 has been selected among 40 Bifidobacterium isolates for its good synergy with a selection of probiotics among which inulin, FOS and GOS [Crittenden, 2001; Su, 2007].

Beyond gut health

B. lactis Lafti® B94 demonstrated its ability to activate bile acids metabolism in a clinical study involving 103 healthy overweight adults [Culpepper, 2019]

Scientific reference(s)

Erdogan et al. (2012). “The comparition of the efficacy of two different probiotics in rotavirus gastroenteritis in children.” Journal of Tropical Medicine Volume 2012, Article ID 787240.

İşlek et al. (2014). “The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children.” Turk J Gastroenterol 25: 628-33.

Basturk, A., et al. (2016). “Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial.” Turk J Gastroenterol 27: 439-43.

Additional info

Therapeutical area(s)

Gastrointestinal tract


Constipation · Diarrhea


Adults · Children
Scroll to Top
Browse companies by type
Brought to you by